Objective: The objective of this paper is to review the randomized controlled trials (RCTs) on the pharmacotherapy of Alzheimer's disease and other dementias and to provide evidence-based recommendations for treatment of the cognitive impairment associated with these disorders.
two-thirds of those being caused by AD (1) . Further, the incidence of dementia doubles for every 5 years of increased age over 65 years, suggesting that there would be over 60 000 new cases of dementia diagnosed in Canada each year (2) . In the absence of interventions to delay onset of these illnesses, we expect over 750 000 patients in Canada with dementia by 2031 (1) . The annual cost of caring for patients with dementia has been estimated to range from $9451 per patient with mild disease to $36 794 per patient with severe disease (3) , with an average net cost in Canada of about 4 billion dollars (4) . With the aging of our society, these illnesses clearly represent a major health problem.
Diagnostic classification systems for AD have focused on cognitive impairment, including memory deficits, aphasia, apraxia, agnosia, and disturbances in executive functioning (5, 6) . The dementias, however, are not simply disorders that cause cognitive impairment. They severely impair instrumental and, eventually, basic activities of daily living (ADL) and cause a multitude of behavioural disturbances that are frequently associated with much greater caregiver burden than are the memory problems. Therefore, a comprehensive management plan would need to consider optimizing general physical health (including sensory organs), improving (also known as enhancing) cognition, delaying illness progression, and treating behavioural disturbances. Assessing and treating physical and emotional problems in caregivers of these patients is also a crucial part of dementia management.
Psychiatry has long been in the forefront of diagnosis and management of dementia patients. Still, with the rapid increase in research in the past decade and the introduction of new treatments, we increasingly face having to familiarize ourselves with new medications, such as completely new therapeutic drug classes, often with multiple and conflicting treatment guidelines. This review examines the data on the pharmacologic management of the cognitive and functional impairment caused by AD and other dementias. Although the focus is on drug treatments, it must be emphasized that these are only a small part of the treatment options that are available and that should be used to manage these illnesses. Recent studies on lifestyle interventions, including participation in physical activities (7) and mentally challenging activities (8) , have demonstrated significant benefit for improving cognition and delaying illness progression. This review will not cover the management of behavioural and psychological symptoms of dementia (9) nor the management of caregiver stress (10) , which have been reviewed elsewhere.
Methods
A Medline search of the English literature from January 1980 to May 2002 was conducted, using the following key words: Alzheimer, dementia, therapy, cholinesterase inhibitor, donepezil, rivastigmine, and galantamine. All randomized controlled trials (RCTs) were reviewed, with emphasis on therapeutic options, currently available in Canada. Following a summary of these studies, organized by a purported mechanism of action (for example, cholinesterase inhibitors, hormone replacement therapy, antiinflammatory therapy, and vascular risk factor management) major treatment guidelines are reviewed. Finally, recommendations are provided based on best current evidence.
Review
Cholinesterase Inhibitors Deficits in the cholinergic system are one of the bestdocumented neurochemical disturbances in AD. The activity of choline acetyltransference-the enzyme that converts choline to the neurotransmitter, acetylcholine-is significantly reduced in the cerebral cortex and in the hippocampus of AD patients. The nucleus basalis of Meynert, the main cholinergic input to the hippocampus, amygdala, and neocortex, demonstrates significant neuronal degeneration. These deficits have been shown to correlate with cognitive impairment and, for this reason, have been a target of therapeutic interventions for several years (11) . Unfortunately, treatments that involve precursor loading and direct cholinergic agonists have been ineffective or poorly tolerated, but with the use of the cholinesterase inhibitors (ChEI), treatment was shown to be effective with an acceptable side effect profile. These drugs inhibit acetylcholinesterase, the enzyme responsible for the breakdown of acetylcholine, effectively leaving more acetylcholine available in the synapse to interact with postsynaptic receptors. It has now been about 15 years since the publication of the original tacrine study that formally opened the door to AD pharmacotherapy (12) . Although this medication was eventually approved for use in the US, poor tolerability and unacceptable hepatotoxicity risk hampered its use, so it was never approved for use in Canada. Subsequently, however, 3 so-called "second-generation ChEIs" (donepezil, rivastigmine, and galantamine) have been approved, based on their efficacy demonstrated in RCTs and their acceptable tolerability profiles (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Donepezil, rivastigmine, and galantamine share several therapeutic properties and have similar side-effect profiles, even though they are pharmacologically distinct agents. As procholinergic drugs, they increase secretions throughout the body, leading to some of their most common side effects, such as nausea, vomiting, and loose stools. Other potential concerns related to cholinergic effects include increasing secretions in the respiratory tract (exacerbating chronic obstructive pulmonary disease [COPD] ) and slowing the heart rate. Dizziness and headache are also reported, though these are not uncommon in placebo-treated patients. In the RCTs, dropouts owing to adverse events were actually quite small, approximately 13%, compared with 6% in the placebo-treated patients (unpublished research). Because of these cholinergic effects, clinicians should use caution when prescribing these drugs in patients with a history of COPD, peptic ulcer disease, and certain cardiac conditions; namely, sick-sinus syndrome, supraventricular conduction abnormalities, active coronary artery disease, and congestive heart failure.
Given the progressive deteriorating nature of this illness, managing patient and caregiver expectations about treatment is crucial. Most ChEI studies have been conducted for 3 to 6 months in patients with mild to moderate disease (10 to 26 out of 30 on the Mini-Mental State Examination [MMSE] [29] ). These studies have generally utilized the Alzheimer's Disease Assessment Scale (ADAS-cog) (30) as a primary cognitive outcome measure, as well as a structured clinical global impression measurement. The ADAS-cog is a 70-item scale that tests various cognitive domains and is more sensitive to change than is the MMSE. AD patients with moderate disease tend to worsen by 7 to 8 points on the ADAS-cog yearly (31) . A change of 4 or more points (that is, representing 6 months of cognitive life for an AD patient) has arbitrarily been chosen as a measure of significant improvement in many of these trials. The pivotal ChEI studies consistently showed that average ADAS-cog scores at the end of the studies were statistically better in drug-treated patients, compared with placebo, whereas the number of patients who experienced significant benefit as defined above was modest, about 30% for drugtreated patients, compared with 18% of placebo-treated patients (unpublished research). Results of the clinical global impression ratings for patients demonstrating minimal, moderate, and marked improvement on ChEIs, compared with placebo were similar. Because most clinicians will be unable to perform an ADAS-cog in their office, measuring cognitive improvement-especially over a period of less than 1 year-can be challenging. However, obtaining a history from caregivers that suggests a decrease in apathy and improved function and communication abilities will often suffice as markers of ChEI response. Most provincial drug formularies reimburse patients for the use of ChEIs when prescribed for AD patients with documented MMSE scores of 10 to 26. On average, the MMSE declines by only 3 points yearly (32) ; for this reason, as an outcome measure for clinicians, the instrument should be used for longer-term use only (1 year) . Despite what appears to be modest efficacy, increasing evidence exists that these drugs have significant effects on functional abilities, behaviour, caregiver burden, and quality of life (33) . In addition, studies suggest that clinicians can achieve significant cost savings, despite the significant initial costs of these drugs (34, 35) . Finally, there is some evidence that these drugs have disease-modifying effects and have benefits beyond cholinesterase inhibition (36) . For example, a recent study documented effects on amyloid precursor protein metabolism, suggesting a possible effect on amyloid plaque deposition (37) .
With the availability of 3 ChEIs, clinicians are faced with deciding which drug to choose. Although no published head-tohead studies exist, examination of individual published efficacy and side-effect rates appear to overlap significantly (unpublished research). They are all safe with respect to potential drug interactions. Donepezil and galantamine are metabolized by CYP 2D6 and 3A4, though extensive drug-interaction testing suggests few clinically important interactions (38) (39) (40) (41) (42) . Rivastigmine undergoes hydrolysis, making it less likely for involvement in significant drug interactions (43) . Because these drugs are marketed at similar prices, economic considerations are insignificant, but from a practical administration perspective, they differ. Donepezil is a once-daily medication, which is initiated at 5 mg and increased to 10 mg after 1 month (1-dose titration step) (44) . Galantamine is administrated twice daily, starting at 4 mg twice daily, with an increase to 8 mg twice daily after 1 month. The manufacturer recommends that the dosage be increased to 12 mg twice daily after a further month (2-dose titration steps); this "might provide additional benefit for some patients" (44) . In fact, most of the pivotal galantamine studies used dosages of 24 to 32 mg daily (24) (25) (26) (27) (28) . Rivastigmine is administered twice daily, beginning with 1.5 mg twice daily, with dosage increases to 3 mg twice daily, 4.5 mg twice daily, and 6 mg twice daily (3-dose titration steps) after a minimum of 2 weeks between dosage changes and dependent on tolerability (44) . Should differences in ease of administration guide clinician choice of ChEI? Not necessarily. These 3 drugs have distinct pharmacologic profiles. Donepezil is a piperidine that is highly specific for acetylcholinesterase with high central, compared with peripheral, cholinomimetic activity. Rivastigmine is a carbamate that is a pseudo-irreversible inhibitor of cholinesterases. Unlike donepezil, it inhibits both acetylcholinesterase and butyrylcholinesterase. The latter becomes increasingly prevalent as AD progresses and may play a role in AD symptomatology, especially in late stages of the illness. Galantamine is a competitive reversible inhibitor of acetylcholinesterase, and it allosterically modulates nicotinic receptors, enhancing cholinergic activity. While the clinical significance of these pharmacologic differences awaits headto-head trials, they do suggest that lack of effectiveness or poor tolerability of 1 agent may not occur with the other 2. This situation would be analogous to using a second (or third) selective serotonin reuptake inhibitor (SSRI) to treat a depression patient who has not responded to the first, given their distinct chemical structures and binding specificities. Preliminary data supporting the practice of switching suggest that, indeed, a second ChEI may be better tolerated and more effective, regardless of the switched-to-or-from agent (45) .
It has also become increasingly clear that the indications for ChEI can be extended beyond AD patients who score 10 to 26 on the MMSE. In a study of patients with moderate-to-severe AD (MMSE scores 5 to 17 out of 30), 63% of donepeziltreated patients were rated as improved or unchanged at 6 months, compared with 42% of placebo-treated patients (20) . The investigators argue that these results are even better than are studies treating mild-to-moderate disease. This study, combined with data that demonstrate neuropathological cholinergic markers do not fall appreciably until later stages of AD, provides support for the use of ChEIs in moderate and severe AD (46) . In an RCT with rivastigmine, 120 patients with dementia with Lewy bodies (DLB) improved significantly on measures of behaviour and cognition, compared with placebo-treated patients (47) . Similarly, other open-label studies suggest positive responses in DLB patients who are treated with donepezil and rivastigmine (48, 49) . In a recently published study, 592 patients with vascular dementia (VaD) or AD and cerebrovascular disease were randomized to 6 months of treatment with either galantamine or placebo (50) . Patients treated with galantamine had significantly better cognitive function, compared with placebo, with results appearing strikingly similar to the ChEI studies in AD. Although these data provide strong argument with respect to expanding the indications for ChEI for moderate-to-severe AD, DLB, and VaD, some caution is necessary before deeming these drugs to be innocuous cure-alls. ChEIs are unhelpful in patients with frontotemporal dementia who generally have no significant cholinergic deficits, and in fact, ChEI treatment may worsen some patients' dementia (51) . For example, in a small RCT in patients with progressive supranuclear palsy, no change occurred in the primary outcome measures of cognition and behaviour, but patients showed significant worsening in ADL mobility measures (52) . Studies currently under way are examining the use of ChEIs in mild AD and MCI (mild cognitive impairment), Down syndrome, Parkinson's disease, and delirium.
Hormone Replacement Therapies
The use of hormone replacement therapy (HRT) to treat AD is based on epidemiological, clinical, and neuropathological observations. It is generally accepted that women have a higher prevalence of AD, compared with men (53) . Women are estrogen-deficient after menopause, whereas men continue to benefit from estrogen coverage throughout life as circulating testosterone undergoes aromatization to estradiol. Significant data reveal that postmenopausal women treated with HRT have improved cognitive function (54) , and a large number of epidemiological studies suggest that women who have undergone HRT are subsequently at lower risk for developing AD (53) . Biological mechanisms proposed for these effects have included estrogen's antioxidant and antiinflammatory properties, interactions with neurotransmitter systems such as acetylcholine, neurotrophic effects (including direct effects on basal forebrain cholinergic neurons), alterations of apolipoprotein E and beta-amyloid levels via stimulation of secretase metabolism, and increased cerebral blood flow and glucose utilization (55, 56) . Unfortunately, despite the enthusiasm for this biologically plausible treatment, several large, well-designed, placebo-controlled RCTs of estrogen replacement in women with AD were negative (57, 58) . A potential criticism of these studies is that using HRT in women who already have the disease is akin to "shutting the barn door after the horses have bolted," and the use of HRT should be directed at postmenopausal women who do not have the disease to prevent or delay onset of the illness (59) . Although such studies are underway in Canada and the US, a large RCT published recently has once again dampened enthusiasm. In this study, 7705 postmenopausal women were randomized to receive placebo or raloxifene, a selective estrogen receptor modulator (60) . After 3 years, raloxifene did not demonstrate any effects on improving cognition or on slowing cognitive decline, compared with placebo. Further studies still need to address issues, such as the type of HRT used (for example, conjugated estrogens vs 17 beta-estradiol (61) or estrogen alone vs estrogen plus progesterone), timing of HRT, whether HRT may have augmenting properties when combined with ChEIs (62), or whether there is a role for HRT in men (63) . At the moment, however, insufficient evidence-based data exist for clinicians to recommend HRT use for AD patients.
Antiinflammatory Therapies
Similar to the experience with HRT, antiinflammatory therapy for AD is a biologically plausible treatment that has yet to be proven clinically valuable in RCTs. It has long been known that markers of inflammation are present in the neuropathology of AD, including reactive microglia surrounding plaques, activated complement, and the presence of numerous acute phase markers (64) . Supported by several epidemiological studies suggesting that patients exposed to nonsteroidal antiinflammatory drugs (NSAIDs) have a lowered risk of developing AD (65) , investigators have studied a number of different antiinflammatories in RCTs. A small, early pilot study with indomethicin appeared positive (66) , whereas more recent studies with diclofenac (67), prednisone (68) , and hydroxychloroquine (69) were all negative. A recent epidemiological study, however, provides a possible explanation for the failure of these RCTs. The Rotterdam study followed 7000 subjects without dementia age 55 years and over for up to 8 years (70) . Based on a review of pharmacy records, that study determined that the relative risk of developing AD was dramatically reduced by NSAID use, but only in subjects who used these drugs for 2 or more years. It also appeared that most of this protective effect occurred prior to 2 years, before dementia was diagnosed. These results suggest that NSAID therapy for AD may require prolonged use for periods well before clinical symptoms are evident. Notably, NSAIDs, steroids, and hydroxychloroquine have overlapping but different pharmacologic properties, making it unclear which of these might provide clinical benefit. Several studies are under way with cycloxygenase 1 and cycloxygenase 2 inhibitors in AD and MCI patients, which will help clarify their role. Presently, however, there are insufficient evidence-based data to recommend antiinflammatory use for the treatment of AD.
Antioxidant Therapies
Neuropathological data suggest that oxidative stress and the accumulation of free radicals lead to neuronal damage in AD (71) . Therefore, several studies have attempted to use compounds with antioxidant effects to treat AD. In the largest study to date, 341 AD patients were randomized to treatment with the antioxidants vitamin E, selegiline, and the combination or placebo (72) . Unfortunately, the study suffered from a failed randomization that resulted in no significant differences in the unadjusted analysis. With statistical adjustment for differences in baseline cognition, vitamin E and selegiline appeared to delay progression of AD by 7 to 8 months over a period of 2 years. Aside from the methodological issue described, other concerns raise the question of result validity; specifically, the choice of outcome measures, the lack of demonstrable effect on cognition, and the use of high dosages of vitamin E (2000 IU daily). With the recent failure of vitamin E to demonstrate cardioprotective and anticancer effects (73) , clinicians may be less likely to recommend vitamin E, even with its well-established safety. Research continues on the use of antioxidant vitamins, and a large US study is attempting to clarify the role of vitamin E in the treatment or prevention of AD. Other compounds with more powerful antioxidant effects are also being studied. For example, a small RCT with N-acetyl cysteine, which has a broader range of activity to neutralize reactive intermediates, suggested that it was well tolerated with possible effects on cognition and ADL (74) .
Treatment of Vascular Risk Factors
Treatment of vascular risk factors may become a crucial component of AD pharmacotherapy. That patients can suffer from mixed AD and VaD has long been recognized, but the contribution to "pure" AD of smaller vascular lesions has been appreciated only recently. In "The Nun Study," investigators studied patients with neuropathologically diagnosed AD and determined that patients with any infarcts-and especially lacunar infarcts in the basal ganglia, thalamus, or deep white matter-were more cognitively impaired and more likely to meet clinical criteria for dementia (75) . Epidemiological studies suggest that patients with hypertension are more likely to develop cognitive impairment, but treatment with antihypertensives lowered the risk (76) . Most persuasively, in a large RCT, 2418 subjects with hypertension, but no dementia, were randomized to antihypertensive therapy with nitrendipine, a calcium channel blocker, or placebo and followed for an average of 2 years (77). Results indicated that treatment with a calcium channel blocker, reduced the incidence of dementia by 50%. Surprisingly, most reduction was due to a decrease in the number of patients diagnosed with AD. In a large epidemiological study, older subjects who were prescribed statins for hypercholesterolemia had a substantially lower risk of developing dementia (78) . Finally, it is well documented that elevations in serum levels of homocysteine are a risk factor for cardiovascular disease and stroke. Recent data from the Framingham study concluded that increased plasma homocysteine is a strong independent risk factor for developing dementia (79) . The authors suggest that vitamin therapy and dietary supplementation with folic acid, Vitamin B6, and B12 could reduce plasma homocysteine levels and possibly decrease the risk of developing dementia.
Other Agents
Various other pharmacologic approaches to treat AD have been studied. A large RCT with Gingko biloba suggested that it had modest effects at improving cognition (80) . A recent review by the Canadian Coordinating Office for Health Technology Assessment concluded that results of available trials on the use of Gingko biloba for dementia suggest smaller effects than those of the ChEIs (81) . Gingko biloba is a plant extract that contains numerous pharmacologically active components, some of which have been theorized to act as antioxidants, antiinflammatories, or neurotransmitter modulators. Because it is unknown which of the active components contribute to its cognitive enhancing effects and the standardized preparations are not available, many clinicians are unlikely to recommend its use. Cerebrolysin is a peptide compound made from porcine brain proteins and theorized to have neuroprotective effects (82, 83) . The need to administer this compound by intravenous (IV) infusion may limit its practical use. Memantine is a glutamate-gated N-methyl-Daspartate (NMDA) receptor channel blocker that has shown promise in treating patients with severe dementia (84) . The search for immunotherapy to block beta-amyloid deposition has also appeared promising, even though research on one vaccine was recently halted due to adverse effects (85) . Finally, several pharmaceuticals that also attempt to block amyloid deposition by acting as secretase inhibitors are in the early stages of development.
Clinical Practice Guidelines
Clinical Practice Guidelines (CPG) are systematically and formally defined recommendations for health care providers that help with decision making on interventions for specific clinical problems (86 (87) . At that time, available drug interventions were limited, but recommendations that patients with mild to moderate AD "may be offered" treatment with tacrine or donepezil was supported by "substantial clinical confidence." Treatment with vitamin E ("substantial clinical confidence") or selegiline ("moderate clinical confidence") could also be considered. Second, later that year, in October 1997, the American Association of Geriatric Psychiatry, the Alzheimer Association, and the American Geriatric Society published a consensus statement on the Diagnosis and Treatment of Alzheimer's Disease and Related Disorders (88) . Once again, the availability of data limited recommendations, but they also suggested that physicians "may consider" a trial of tacrine or donepezil for patients with mild to moderate AD. In contrast to the APA Guidelines, they noted that the evidence for the clinical use of Gingko biloba, vitamin E, and selegiline was "inconclusive." Third, in June 1999, the Canadian Consensus Conference on Dementia published the guidelines that were more far-reaching, comprehensive, and comprised several pharmacologic recommendations (89) . When present, physicians should treat vascular risk factors, including arterial hypertension, hypercholesterolemia, diabetes mellitus, smoking, use of anticoagulation for atrial fibrillation, and secondary prevention of transient ischemic attacks (TIAs) and stroke. The use of NSAID and HRT was not recommended on the basis of available evidence. The guidelines recommended that donepezil "can be prescribed to informed and willing patients with mild to moderate dementia due to probable AD," though they also noted that no evidence supported the use of the drug in preventing AD or the treatment of more severe stages. With respect to the use of vitamin E and Gingko biloba, there was insufficient evidence to recommend their use; conversely, a dissenting opinion was published which argued that vitamin E had been shown to slow progression of AD and that there was potential for additional health benefits with its use.
The limitations of CPGs have been well documented, not the least of which is poor physician adherence (90) . The CPGs reviewed above are clearly outdated: numerous pivotal trials and important studies have been published since 1999. In fact, in the year 2001 alone, over 30 major studies on AD pharmacotherapy were published, most of which have direct implications for CPGs (91) . Without electronic posting of such guidelines and frequent regular "live updates," all dementia CPGs will likely be outdated by their date of publication-a true testament to the expansion of research in this area of therapeutics.
Recommendations and Conclusions
Based on the previous review, evidence-based recommendations for the pharmacotherapy of AD and other dementias can be made. Regardless of etiology, physicians should pay particular attention to vascular risk factors-and especially ensure adequate treatment and monitoring of hypertension, diabetes, and cholesterol levels. Clinicians should provide anticoagulation or antiplatelet therapy for patients with a history of TIAs or stroke. Although RCT evidence is lacking, recommending a multivitamin with folate and B-complex vitamins may decrease homocysteine levels and, most likely, will be well tolerated (and well accepted by most patients). Clinicians should offer patients with AD, VaD, and DLB at least 1 trial of a ChEI, while considering a second ChEI if the first is not tolerated or is ineffective. ChEI use in AD should be considered not only in patients with mild-to-moderate illness but also in cases of moderate-to-severe illness. In dementia patients, HRT and antiinflammatory treatment should not be prescribed as the primary therapeutic indication at this time. The use of Gingko biloba cannot be recommended, owing to insufficient data and practical administration issues. However, physicians could consider the use of vitamin E, although more data are necessary to recommend its use with any confidence, and recent studies have dampened the enthusiasm for benefits beyond dementia.
Most patients who follow these recommendations will have only modest cognitive or disease-modifying benefits, but even modest benefits may have significant effects on quality of life, caregiver burden, and societal economic costs. Nevertheless, these interventions clearly represent only the first small steps on a long voyage that will eventually see treatments that can prevent onset, delay progression, and reverse the cognitive, functional, and behavioural disorders that plague our patients.
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Janssen-Ortho Inc, Pfizer, and Novartis provided honoraria, consultant fees, and research support for this study. Méthode : Une recherche des études contrôlées randomisées a été menée dans Medline, à l'aide des mots clés suivants : maladie d'Alzheimer, démence, thérapie, inhibiteur de la cholinestérase, donepezil, rivastigmine et galantamine. Les études ont fait l'objet d'une analyse critique, suivie d'une revue des principales lignes directrices cliniques publiées. Des recommandations de traitement ont été faites en fonction des meilleures données probantes disponibles.
Résultats : La pharmacothérapie de la maladie d'Alzheimer devrait inclure la gestion méticuleuse des facteurs de risque vasculaires (par exemple, l'hypertension, le diabète, le cholestérol et la prévention des accidents cérébro-vasculaires), et l'ajout éventuel de suppléments comme l'acide folique, la vitamine B complexe et la vitamine E. On devrait offrir aux patients au moins un essai d'inhibiteur de la cholinestérase et la possibilité d'un autre essai si le premier est mal toléré ou inefficace. On devrait aussi offrir le traitement aux inhibiteurs de la cholinestérase aux patients souffrant de démence vasculaire ou de démence à corps de Lewy. À l'heure actuelle, nous n'avons pas suffisamment de données pour recommander comme indication principale le recours à l'hormonothérapie substitutive ou aux anti-inflammatoires pour le traitement de la démence.
Conclusion :
Des preuves raisonnables justifient de recommander la pharmacothérapie de la démence. Le traitement aura sans doute pour résultat des avantages modestes mais importants pour les patients, les fournisseurs de soins et la société.
